A 48-Week, Randomised, Study to Describe the Pharmacokinetic Profile and Durability of Atazanavir-Saquinavir-Ritonavir Once Daily and Describe the Pharmacokinetic Profile of Saquinavir-Ritonavir Using Saquinavir 500mg Formulation.
Phase of Trial: Phase II
Latest Information Update: 13 Jun 2016
At a glance
- Drugs Saquinavir (Primary) ; Atazanavir; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Acronyms ASK500
- 10 Jun 2017 Biomarkers information updated
- 30 Jun 2009 Additional trial acronym ASK-500 identified as reported by ClinicalTrials.gov.
- 30 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History